Autoimmune diseases (ADs), which are common immune-mediated inflammatory syndromes, are characterized by an imbalance between T effector (Th)1/Th17 cells and T regulatory cells. Interleukin (IL)-33, a member of the IL-1 family, induces inflammatory disease development by mediating type 2 immune responses. Recently, IL-33/ST2 axis was reported to induce autoimmunity involving Th1 and Th17 cells. In this review, we focus on the expression, regulation and function of IL-33/ST2 pathway in the context of autoimmune disorders. We discuss the clinical potential of this signaling pathway in predicting disease activity and severity and offer possible future therapeutic alternatives.

自身免疫性疾病（ADs）是常见的免疫介导的炎症综合征，其特征在于T效应（Th）1 / Th17细胞与T调节细胞之间的失衡。IL-1家族的成员白介素（IL）-33通过介导2型免疫反应诱导炎症性疾病的发展。最近，据报道IL-33 / ST2轴诱导涉及Th1和Th17细胞的自身免疫。在这篇综述中，我们着重于自身免疫性疾病中IL-33 / ST2途径的表达，调控和功能。我们讨论该信号通路在预测疾病活动和严重程度方面的临床潜力，并提供未来可能的治疗选择。